Summary
The pharmacokinetics of cefotaxime, its desacetyl metabolite and ceftriaxone were studied in 72 patients with various degrees of renal and hepatic failure. Patients with severe renal failure (creatinine clearance 3 to 10 ml/min) had a cefotaxime serum half-life of 2.6 h, a desacetyl cefotaxime serum half-life of 10 h and ceftriaxone serum half-life of 17 h. In the case of ceftriaxone, this serum half-life could be very variable — increasing to over 50 h, possibly due to co-existing hepatic dysfunction. Increases in serum half-life were found for cefotaxime in the presence of liver disease.
Zusammenfassung
Die Pharmakokinetik von Cefotaxim, seines Desacetyl-Metaboliten und von Ceftriaxon wurde bei 72 Patienten mit unterschiedlichem Grad an Nieren- und Leberinsuffizienz untersucht. Patienten mit schwerer Niereninsuffizienz (Kreatinin-Clearance 3 bis 10 ml/min) hatten eine Cefotaxim-Serumhalbwertszeit von 2,6 Stunden; die Halbwertszeit von Desacetyl-Cefotaxim betrug 10 Stunden und von Ceftriaxon 17 Stunden. Bei Ceftriaxon variierten die Halbwertszeiten sehr stark und stiegen auf über 50 Stunden an, möglicherweise ist dies auf eine gleichzeitig bestehende Leberinsuffizienz zurückzuführen. Bei Patienten mit Leberinsuffizienz wurden erhöhte Halbwertszeiten für Cefotaxim gefunden.
Similar content being viewed by others
Literature
Fu, K. P., Neu, H. C. Beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin. Antimicrob. Agents Chemother. 14 (1978) 322–326.
Wise, R., Gillett, A. P., Andrews, J. M., Bedford, K. A. Ro 13-9904: a new cephalosporin with a high degree of activity and broad antibacterial activity: anin vitro comparative study. J. Antimicrob. Chemother. 6 (1980) 595–600.
McKendrick, M. W., Geddes, A. M., Wise, R. Clinical experience with cefotaxime (HR-756). In:Nelson, J. D., Grassi, C. (eds.): Current chemotherapy and infectious disease. Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Vol. 1., American Society for Microbiology, Washington, D.C. 1980, pp. 123–125.
Wise, R., Wills, P. J., Andrews, J. M., Bedford, K. A. Activity of cefotaxime (HR-756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob. Agents Chemother. 17 (1980) 84–86.
Seddon, M., Wise, R., Gillett, A. P., Livingston, R. Pharmacokinetics of Ro 13-9904, a broad spectrum cephalosporin. Antimicrob. Agents Chemother. 18 (1980) 240–242.
Levy, G., Gibaldi, M. Pharmacokinetics. In:Gillette, J. R., Mitchell, J. R. (eds.): Handbook of experimental pharmacology new series: concepts in biomedical pharmacology. Vol. 28, Springer-Verlag, Berlin 1975, pp. 6–18.
Leevy, C. M., Smith, F., Longueville, J., Paumgartner, G., Howard, M. M. Indocyanine Green clearance as a test of hepatic function. JAMA 900 (1967) 236–400.
Wise, R. A review of antibiotic pharmacology. In:Reeves, D. S., Phillips, I., Williams, J. D., Wise, R. (eds.): Laboratory methods in antimicrobial chemotherapy. Churchill Livingstone, Edinburgh 1978, pp. 144–150.
Stöckel, K.: Single dose pharmacokinetics of ceftriaxone in physiological anephric patients. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C. 1981, Abstract 387.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wise, R., Wright, N. The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction. Infection 13 (Suppl 1), S145–S150 (1985). https://doi.org/10.1007/BF01644237
Issue Date:
DOI: https://doi.org/10.1007/BF01644237